Group 1 - The company, Aomei Medical (002950.SZ), announced a share buyback program, having repurchased a total of 1.9874 million shares as of July 31, 2025, which represents 0.3138% of its total share capital [1] - The highest transaction price during the buyback was 9.26 yuan per share, while the lowest was 8.33 yuan per share [1] - The total amount spent on the share buyback was 18.0012 million yuan, excluding transaction fees such as stamp duty and commissions [1]

证券代码：002950 证券简称：奥美医疗 公告编号：2025-041 奥美医疗用品股份有限公司 关于股份回购进展的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没 有虚假记载、误导性陈述或重大遗漏。 奥美医疗用品股份有限公司（以下简称"公司"）董事会于 2025 年 1 月 20 日召开第 三届董事会第十二次会议，审议通过了《关于以集中竞价交易方式回购公司股份方案的议 案》，同意公司以自有资金及股票回购专项贷款资金通过集中竞价交易方式回购公司股份， 用于股权激励或员工持股计划。本次回购价格不超过人民币 11.00 元/股（含），回购股份 的资金总额不低于人民币 5,000 万元（含）且不超过人民币 10,000 万元（含），具体回购 资金总额以实际使用的资金总额为准。回购股份的实施期限为自公司董事会审议通过本次 回购方案之日起 12 个月内。具体内容详见公司分别于 2025 年 1 月 22 日、2025 年 1 月 24 日披露于巨潮资讯网（www.cninfo.com.cn）等指定信息披露媒体的《关于回购公司股 份方案暨取得股票回购专项贷款的公告》（公告编号：2025-001）和《关于 ...

奥美医疗用品股份有限公司 信息披露义务人：陈浩华 住所及通讯地址：广东省深圳市南山区龙珠四路 X 号 股份变动性质：减持 签署日期：2025 年 8 月 1 日 简式权益变动报告书 信息披露义务人声明 上市公司名称：奥美医疗用品股份有限公司 股票上市地点：深圳证券交易所 股票简称：奥美医疗 股票代码：002950 截止本报告书签署之日，除本报告书披露的信息外，信息披露义务人没有通过任何 其他方式增加或减少其在奥美医疗拥有权益的股份； 四、本次权益变动是根据本报告所载明的资料进行的。除本信息披露义务人外，没 有委托或者授权任何其他人提供未在本报告书中列载的信息和对本报告书做出任何解 释或者说明； 五、信息披露义务人承诺本报告不存在虚假记载、误导性陈述或重大遗漏，并对其 真实性、准确性、完整性承担个别和连带的法律责任。 | 第一节 | 信息披露义务人介绍 5 | | --- | --- | | 第二节 | 权益变动的目的及计划 6 | | 第三节 | 权益变动方式 7 | | 第四节 | 权益变动前 6 个月内买卖上市公司股份的情况 9 | | 第五节 | 其他重大事项 10 | | 第六节 | 备查文件 11 ...

公司持股 5%以上股东陈浩华保证向本公司提供的信息内容真实、准 确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一 致。 特别提示： 证券代码：002950 证券简称：奥美医疗 公告编号：2025-040 奥美医疗用品股份有限公司 关于持股 5%以上股东权益变动暨 披露简式权益变动报告书的提示性公告 1.本次权益变动属于公司持股 5%以上股东陈浩华先生将其持有的公司股份 通过大宗交易形式减持导致其持有公司股份数量和比例减少。 2.本次权益变动不涉及控股股东及一致行动人增持或减持，不触及要约收 购，不会导致公司控股股东及实际控制人发生变化，不会影响公司的治理结构 和持续经营。 3.关于本次权益变动的具体内容详见公司同日在巨潮资讯网披露的《简式 权益变动报告书》。 1.陈浩华先生本次权益变动遵循减持计划公告，与此前披露的减持计划一 致，符合《公开发行证券的公司信息披露内容与格式准则第 15 号——权益变动 报告书（2025 年修订）》等有关规定的情形。 2.本次权益变动不触及要约收购，不会导致公司控股股东及实际控制人发 生变化，不会影响公司的治理结构和持 ...

Company Overview - Aomei Medical specializes in the research, production, and sales of medical consumables, disposable medical devices, infection protection products, and home care products [2] - The main products include surgical and wound care, infection protection, advanced dressings, and hygiene care [2] Financial Performance - For Q1 2025, the company reported revenue of 759 million yuan, a year-on-year increase of 1.64% [3] - Net profit for the same period was 86.5 million yuan, reflecting a year-on-year decrease of 7.86% [3] - The gross profit margin stood at 30.52% [3] Market Position - As of August 1, Aomei Medical's stock closed at 9.36 yuan, with a rolling PE ratio of 16.41, marking a new low in 95 days [1] - The company's total market capitalization is 5.927 billion yuan [1] - In comparison to the industry, the average PE ratio for the medical device sector is 53.65, with a median of 37.22, placing Aomei Medical at the 37th position in the industry [1] Shareholder Information - As of March 31, 2025, Aomei Medical had 39,155 shareholders, a decrease of 2,201 from the previous count [1] - The average market value of shares held by each shareholder is 352,800 yuan, with an average holding of 27,600 shares [1] Industry Recognition - Aomei Medical has received multiple accolades, including being listed among the top 100 private manufacturing enterprises in Hubei in 2022 and recognized for its intelligent manufacturing demonstration factory project [2]

Core Viewpoint - Aomei Medical's stock price closed at 9.26 yuan on July 31, 2025, reflecting a decrease of 0.54% from the previous trading day, with a trading volume of 54,716 lots and a transaction amount of 0.51 billion yuan [1] Company Overview - Aomei Medical specializes in the research, production, and sales of disposable medical consumables, including wound care, surgical infection control, and infection prevention products, with a global market presence [1] - The company has maintained its leading position in China's medical dressing export industry for 17 consecutive years [1] Recent Developments - Aomei Medical has signed a strategic cooperation agreement with the German Lohmann & Rauscher Group to acquire 100% equity of its wholly-owned subsidiary in China, gaining exclusive agency rights for related products in the Chinese market [1] - This collaboration will enhance Aomei Medical's product line in China, particularly in the fields of wound management, pressure treatment, and external fixation [1] - The partnership builds on a commercial cooperation foundation established since 2006, indicating a deepening of the relationship between the two companies [1]

Core Viewpoint - Aomei Medical has signed a comprehensive cooperation agreement with Lohmann & Rauscher Group, marking a significant strategic partnership that includes the acquisition of Lohmann & Rauscher's wholly-owned subsidiary in China and exclusive agency rights for various medical products in the region [1][2]. Group 1: Strategic Partnership - The partnership involves Aomei Medical acquiring 100% of Lohmann & Rauscher (China) Medical Supplies Co., Ltd. and gaining exclusive agency rights for wound management, pressure treatment, and external fixation products in China [1]. - This collaboration is a continuation of their strategic cooperation that began with a functional dressing business partnership in November 2024, further solidifying their multi-layered strategic alliance [1][2]. Group 2: Market Position and Product Development - Aomei Medical has been focusing on the research and manufacturing of functional dressings, launching innovative products such as soft silicone foam dressings and hydrocolloid dressings, which cater to various wound care scenarios [2]. - The partnership enhances Aomei Medical's product pipeline in the wound management sector and allows entry into new fields like pressure treatment and external fixation, significantly boosting its competitive edge in the Chinese market [2]. Group 3: Leadership Perspectives - The CEO of Lohmann & Rauscher Group expressed confidence that the partnership will lead to higher quality and more sustainable product development, highlighting Aomei Medical's production capabilities [2]. - Aomei Medical's chairman emphasized that this collaboration marks a new beginning in the healthcare sector, aiming for significant achievements in expanding their market presence in China [3].

Core Viewpoint - The recent large block trades in Aomei Medical (002950) indicate significant institutional buying activity, suggesting potential long-term investment interest despite the stock's price discount compared to market value [1][2]. Group 1: Trading Activity - On July 30, Aomei Medical experienced 7 large block trades totaling 5.04 million shares, with a transaction value of 42.99 million yuan, at an average price of 8.53 yuan per share, representing an 8.38% discount to the closing price of 9.31 yuan [1]. - Institutional investors accounted for 6 of the trades, purchasing 4.64 million shares worth 39.58 million yuan, which is 92% of the total transaction value [1]. - The stock's trading volume on the same day was 55.66 million yuan, with large block trades making up 77.24% of this volume [1]. Group 2: Shareholder Activity - On July 21, shareholder Chen Haohua reduced his stake by 4.21 million shares, representing 0.67% of the total share capital, bringing his holding to 10.87% [2]. - The subsequent three days of large block trades were linked to the same brokerage firm involved in Chen's share reduction, indicating that institutions may have been the primary buyers of the sold shares [2]. Group 3: Market Context and Financial Performance - The overall market saw high activity in large block trades, with companies like China Merchants Bank and Hengli Petrochemical also reporting significant transactions [2]. - As of July 30, Aomei Medical's stock price slightly increased by 0.11% to 9.31 yuan, with a total market capitalization of 5.896 billion yuan and a price-to-earnings ratio of 17.04 [2]. - For the first quarter of 2025, Aomei Medical reported revenues of 759 million yuan and a net profit of 86.5 million yuan [2].

Group 1 - As of July 29, 2025, the stock price of Aomei Medical is 9.30 yuan, an increase of 0.43% compared to the previous trading day [1] - The trading volume on that day was 46,085 hands, with a transaction amount of 42.63 million yuan and a fluctuation of 1.62% [1] - Aomei Medical primarily engages in the research, production, and sales of disposable medical consumables, including wound care and surgical infection control products, with exports to multiple countries and regions [1] Group 2 - On July 29, a block trade occurred involving 469,000 shares, with a transaction amount of 4.00 million yuan at a price of 8.53 yuan, representing an 8.28% discount to the closing price [1] - The buyer of the block trade was an institutional special account, and on that day, the net outflow of main funds was 1.86 million yuan [1]

Group 1 - The core transaction involved a block trade of 469,000 shares of Aomei Medical, with a total transaction value of 4,000,600 yuan, accounting for 8.58% of the total trading volume on that day [1][2] - The transaction price was set at 8.53 yuan per share, which represents an 8.28% discount compared to the market closing price of 9.30 yuan [1][2] - The buyer was an institutional investor, while the seller was from Dongfang Securities Co., Ltd., specifically their Shenzhen Shennan Avenue branch [2]